The immunology of DLBCL
T Takahara, S Nakamura, T Tsuzuki, A Satou - Cancers, 2023 - mdpi.com
Simple Summary Diffuse large B-cell lymphoma (DLBCL) is the most common type of
malignant lymphoid neoplasm and includes morphologically and molecularly …
malignant lymphoid neoplasm and includes morphologically and molecularly …
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …
Genomic profiling for clinical decision making in lymphoid neoplasms
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Insights into the tumor microenvironment of B cell lymphoma
The standard therapies in lymphoma have predominantly focused on targeting tumor cells
with less of a focus on the tumor microenvironment (TME), which plays a critical role in …
with less of a focus on the tumor microenvironment (TME), which plays a critical role in …
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
M Larrayoz, MJ Garcia-Barchino, J Celay… - Nature Medicine, 2023 - nature.com
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple
myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this …
myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this …
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial
MC Zhang, S Tian, D Fu, L Wang, S Cheng, HM Yi… - Cancer Cell, 2023 - cell.com
We report the results of GUIDANCE-01 (NCT04025593), a randomized, phase II trial of R-
CHOP alone or combined with targeted agents (R-CHOP-X) guided by genetic subty** of …
CHOP alone or combined with targeted agents (R-CHOP-X) guided by genetic subty** of …
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of
anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care …
anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care …
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas
Activated B-cell-like diffuse large B-cell lymphomas (ABC-DLBCLs) are characterized by
constitutive activation of nuclear factor κB driven by the B-cell receptor (BCR) and Toll-like …
constitutive activation of nuclear factor κB driven by the B-cell receptor (BCR) and Toll-like …
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
B Apollonio, F Spada, N Petrov… - The Journal of …, 2023 - Am Soc Clin Investig
Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has
highlighted the clinical relevance of LN fibroblast and tumor-infiltrating lymphocyte (TIL) …
highlighted the clinical relevance of LN fibroblast and tumor-infiltrating lymphocyte (TIL) …
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity.
The clinical course is variable, multiple genes are mutated with no unifying mechanism, and …
The clinical course is variable, multiple genes are mutated with no unifying mechanism, and …